UNSPSC 51352303: Dimepregnen

This classification denotes a therapeutic progestin with the molecular formula C23H36O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X08N6BOT8Y, chemically known as 3beta-hydroxy-6alpha,16alpha-di-methylpregn-4-en-20-one. but generally known as dimepregnen, which bears US NIH Compound Identifier 208839. European Medicines Agency schedules Dimepregnen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07163MIG.

UNSPSC 51352303 Dimepregnen is a Commodity code covering generic pharmaceutical active ingredients and formulated products supplied through multistate cooperative purchasing arrangements to state and local health facilities. State and local governments procure under this code primarily through cooperative purchasing vehicles, with established wholesaler networks delivering products to participating departments of health, corrections, and other public health agencies. The work involves manufacturers and suppliers certifying compliance with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA), managing National Drug Code (NDC) registrations, and maintaining relationships with authorized wholesale distributors. Pricing structures vary across flat-price, net-price (NF30, NF60, NF90), and WAC-minus formats, with vendors absorbing administrative fees typically ranging from 3 percent of contract value.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP (Solicitation S1070000015802) posted January 20, 2026, seeking multiple awards for generic multi-source pharmaceuticals and over-the-counter products effective July 1, 2026, with proposals due March 26, 2026. The opportunity covers participating state and local facilities in Minnesota and Oregon. Vendors must maintain contractual relationships with at least two of three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and provide products with expiration dates at least one year from manufacture and minimum six-month shelf life. Evaluation weighting emphasizes price competitiveness (75 percent), with smaller allocations for fixed pricing (10 percent), administrative compliance (5 percent), EDI capability (5 percent), and fee acceptance (5 percent). Awards are structured to align with member-specific therapeutic needs and patient safety considerations, with the contract term two years for new responders and optional extensions at MMCAP's discretion.